During approximately the same timeframe, anti-TNF-α agents have revolutionized the treatment of IBD, effectively reducing inflammation and supporting mucosal healing, but over 50% of patients never responded to this therapy, or the responses were not durable [19,55]. This evidence concerns the gene TNF and inflammatory bowel disease.